Prescribing guide
Elelyso (taliglucerase alfa)Dosing, infusion rates, hypersensitivity management and prior authorization criteria for type 1 Gaucher diseaseFor prescribers and their offices treating gaucher disease: what the pharmacy needs before it ships, what the prior authorization wants documented, the titration and the monitoring the label requires.
Dispensing gate
No REMS. Boxed warning: initiate in a healthcare setting with monitoring and CPR equipment. Prior authorization and a site of care before the first infusion.
Example PA threshold
FEP Blue example: age 4 years or older; Gaucher disease type 1; no dual therapy with another type 1 Gaucher medication; 2-year approval.
Monitoring
Supervised infusion with anaphylaxis readiness; observe closely during and after each infusion; closely monitor patients who develop ADA; no laboratory schedule in the label.
Support line
Pfizer Gaucher Personal Support (GPS) 1-855-353-5976; Treatment Request Form fax 1-866-758-7135; co-pay help for eligible commercial plans (confirm current terms with GPS); Pfizer Patient Assistance Program. A March 2024 Pfizer co-pay FAQ listed GPS hours as Monday to Friday, 8 AM to 6 PM ET.
Give your patient their plan
A one-page handout for starting Elelyso, in plain language: what the first fill waits on, the first dates, who will call and the symptoms to report, with blank lines for the start date and your office's number. The link opens the patient's full first 90 days page, where their dates become calendar entries.
trialfriend.com/p/elelysoBefore the first fill: REMS, labs and enrollment
The steps that the pharmacy, the REMS or the drugmaker's program will wait on, in the order they usually need to happen. A first fill of a specialty drug most often stalls on one of these rather than on the plan.
| Step | What it requires | Source |
|---|---|---|
| Start the patient with GPS | Call Pfizer GPS at 1-855-ELELYSO (1-855-353-5976), or fax a Treatment Request Form to 1-866-758-7135. A GPS Case Manager is the patient's primary contact. | Pfizer patient support offerings page |
| Benefits and prior authorization | GPS helps with insurance benefits verification and understanding prior authorization requirements, gives information on the coverage appeals process, and supports patients through an insurance change. | Pfizer access and support page for professionals |
| Site of care | GPS provides a list of infusion sites within a geographic area, checks that Elelyso and supplies are on site, and gives infusion centers administration information. GPS does not provide infusion administration. | Pfizer patient support offerings page |
| Home infusion | GPS can confirm home-health benefits with the insurer; if approved, GPS can contact a specialty pharmacy to set up at-home infusions. The label requires initiation in a healthcare setting. | Pfizer patient support offerings page |
| Calculate vials | 200 unit single-dose vials, one per carton (NDC 0069-0106-01), refrigerated at 2°C to 8°C in the original carton, protected from light. Round the number of vials up to the next whole number. Do not leave vials at room temperature longer than 24 hours before reconstitution. | FDA label |
| Reconstitute | 5.1mL Sterile Water for Injection per vial; mix gently, do not shake; yields 40 units/mL, extractable volume 5mL. If not used immediately: up to 24 hours at 2°C to 8°C protected from light, or up to 4 hours at 20°C to 25°C. | FDA label |
| Dilute | 0.9% sodium chloride to a final volume of 100 to 200mL: 100 to 120mL for pediatric patients; 130 to 150mL for adults, not above 200mL. Diluted solution up to 24 hours at 2°C to 8°C protected from light; total storage from start of preparation no more than 24 hours. | FDA label |
| Co-pay Program | Enroll by phone through GPS, which can explain current co-pay help. No current dollar figure is stated here: on November 11, 2026 the patient page terms still read "Offer expires 12/31/2024". Those posted terms listed as low as $0 per prescription, a $15,000 calendar-year maximum, age 4 or older and no more than 2 redemptions per 30 days. | Pfizer GPS page |
| Co-pay exclusions | Posted terms: not for Medicare, Medicaid, TRICARE, VA, state drug assistance programs or Puerto Rico's Government Health Insurance Plan; not for cash-paying patients. The professional page also excludes Massachusetts residents with third party coverage; its terms read "Offer expires 12/31/2023". | Pfizer access and support page for professionals |
| Co-pay claims | Per Pfizer's March 2024 PfizerCopay.com FAQ: enrollment and claims run through PfizerCopay.com; submit the Pfizer Co-Pay Claim Form within 180 days of the date of service on the Explanation of Benefits. Enrollment renews automatically while the patient remains eligible. | PfizerCopay.com FAQs |
| Patient Assistance Program | Elelyso may be available at no cost to qualified uninsured or government-insured patients who meet financial qualifications, have the FDA-approved indication, are US residents treated by US physicians, and complete the application and authorization form. | Pfizer access and support page for professionals |
Prior authorization criteria and what to document
One public policy as the example: FEP Blue (Blue Cross and Blue Shield Federal Employee Program), April 1, 2026. Approval 2 years. This policy (5.85.014) was last reviewed on March 6, 2026 and cites the December 2025 label, the current one. It lists no specialist, lab report or dose limit among its requirements. It is here as an example of what a plan asks for, not as a rule.
| Element | What the policy asks | In the chart | Source |
|---|---|---|---|
| Age | 4 years of age and older | Date of birth | FEP Blue policy |
| Diagnosis | Gaucher disease, type 1; all other indications considered investigational | Diagnosis in the note | FEP Blue policy |
| Concurrent therapy | No dual therapy with another medication for type 1 Gaucher disease: Cerdelga, Cerezyme, VPRIV, Zavesca or Yargesa | Current medication list | FEP Blue policy |
| Pre-PA allowance | None | Prior approval before the first infusion | FEP Blue policy |
| Approval | 2 years | Approval dates in the chart | FEP Blue policy |
| Renewal | Same requirements as the initial approval; 2 years | Updated medication list at renewal | FEP Blue policy |
Elelyso dosing and titration
| When | Label | Source |
|---|---|---|
| Treatment-naive, 4 years and older | 60 units/kg (actual body weight) IV every other week as a 60- to 120-minute infusion. | FDA label |
| Switching from imiglucerase | If a switch from a stable imiglucerase dosage is acceptable, start at the same units/kg dosage, then every other week. Trial 3: 30 of 31 patients had no dose change over 9 months. | FDA label |
| Adjustment | Dosage adjustments can be made based on achievement and maintenance of each patient's therapeutic goals. | FDA label |
| Infusion rate, adults | Initial 1.2mL/minute; after tolerability is established, may increase to a maximum of 2.2mL/minute. Minimum infusion time 60 minutes. | FDA label |
| Infusion rate, pediatric | Under 30kg: 1mL/minute. 30kg or more: initial 1mL/minute; after tolerability is established, maximum 2mL/minute. | FDA label |
| Administration set | In-line low protein-binding 0.2 micron filter. | FDA label |
| Before infusion | Consider pretreatment with antihistamines and/or corticosteroids to reduce the risk of hypersensitivity reactions. | FDA label |
| Mild reaction | Slow or temporarily interrupt the infusion and/or give antihistamines, antipyretics and/or corticosteroids. | FDA label |
| Severe reaction | Discontinue and immediately initiate treatment, including epinephrine. Consider the risks and benefits of re-administration; exercise caution on rechallenge. | FDA label |
| Under 4 years | Safety and effectiveness not established. | FDA label |
| Missed dose, renal, hepatic | The label gives no missed-dose instruction and no renal or hepatic impairment section. | FDA label |
Monitoring the Elelyso label requires
| When | What | What the label says to do with it | Source |
|---|---|---|---|
| Each infusion | Anaphylaxis: urticaria, hypotension, flushing, wheezing, chest tightness, nausea, vomiting, dizziness (2 of 72, 3%, during infusion) | Can occur early or after extended therapy. Discontinue and treat immediately, including epinephrine | FDA label |
| Each infusion | Hypersensitivity: pruritus, angioedema, flushing, erythema, rash, nausea, vomiting, cough, chest tightness, throat irritation (21 of 72, 29%) | Occurred during infusion and up to 3 hours after its start. Observe closely during and after the infusion | FDA label |
| Observation wording | The July 2024 label said to observe for 3 hours after the start of each infusion | Changed in January 2025 (S-033) to observe closely during and after the infusion | FDA-approved label, July 2024 |
| Pediatric patients | Vomiting (4 of 9 treatment-naive patients) | May be a symptom of a hypersensitivity reaction | FDA label |
| Anti-drug antibodies | ADA developed in 17 of 32 (53%) in Trial 1, 2 of 9 (22%) in Trial 2 and 6 of 26 adults (23%) in Trial 3 | Hypersensitivity in 36% (9/25) with ADA versus 15% (6/41) without; closely monitor patients who develop ADA. The label sets no testing schedule | FDA label |
| Disease response | The label sets no schedule for spleen, liver or hematologic assessments | Trial 1 measured spleen and liver volume by MRI, platelets and hemoglobin at 9 months | FDA label |
| Adverse reaction reporting | Pfizer 1-800-438-1985 or FDA 1-800-FDA-1088 | Postmarketing reports: vomiting, diarrhea, fatigue, anaphylaxis, type III immune-mediated fixed drug eruption, back pain | FDA label |
Elelyso drug interactions and contraindications
| Label category | Agents and what the label says | Source |
|---|---|---|
| Contraindications | None | FDA label |
| Drug interactions | The label has no drug interactions section | FDA label |
| Other Gaucher therapies | Dual therapy with Cerdelga, Cerezyme, VPRIV, Zavesca or Yargesa not approved under the FEP Blue policy; the Elelyso label does not address combination use | FEP Blue policy |
| Pregnancy | Registry and pharmacovigilance data have not identified a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes; untreated symptomatic type 1 disease carries risks; no embryo-fetal toxicity in rats and rabbits at up to 5 times the recommended human dose | FDA label |
| Lactation | No data on presence in human milk or effects on milk production; registry lactation data have not identified adverse reactions in breastfed infants | FDA label |
| Geriatric | 8 patients 65 or older were treated in trials; too few to determine whether they respond differently | FDA label |
Why a first fill stalls, and the fix
- Prior authorization pending or deniedThe FEP Blue policy below asks for a diagnosis of type 1 Gaucher disease and an age of 4 years or older. Pfizer says GPS can explain a plan's prior authorization requirements.
- The request is for another type of Gaucher diseaseFEP Blue treats Elelyso as investigational for anything other than type 1. The label also covers only type 1 Gaucher disease.
- The patient is younger than 4FEP Blue requires an age of 4 years or older. The label says safety and effectiveness have not been established in younger children.
- Also taking another Gaucher medicineFEP Blue does not allow Elelyso together with Cerdelga, Cerezyme, VPRIV, Zavesca or Yargesa. Your doctor decides which treatment fits you.
- The approval has run outFEP Blue approves Elelyso for 2 years at a time. Renewal uses the same requirements as the first approval.
- A copay you cannot payPfizer Gaucher Personal Support (1-855-353-5976) can explain current co-pay help for people with commercial insurance. On November 11, 2026, the co-pay terms on Pfizer's patient page still showed an offer that expired on December 31, 2024.
- Co-pay terms that look out of dateThe co-pay terms posted on Pfizer's patient page set a yearly limit and list an expiry date of December 31, 2024. This page gives no dollar figure for that reason, and GPS can say what applies now.
- Medicare, Medicaid or other government insuranceThe co-pay terms posted on Pfizer's page exclude state and federally funded insurance. Pfizer says Elelyso may be available at no cost to qualified government-insured people through the Pfizer Patient Assistance Program.
- No insuranceThe co-pay terms posted on Pfizer's page are not valid for cash-paying patients. The Pfizer Patient Assistance Program may provide Elelyso at no cost to qualified uninsured people who meet its financial rules.
- You live in MassachusettsThe co-pay terms on Pfizer's page for healthcare professionals exclude Massachusetts residents whose prescriptions are covered by third party insurance. Those terms list an expiry date of December 31, 2023, and GPS can confirm what applies now.
- The plan denies coveragePfizer says GPS can provide information about the insurance coverage appeals process. GPS also offers support when your insurance changes.
Pfizer Gaucher Personal Support (GPS)
- A GPS Case Manager as the main contact for patients, parents and caregivers
- Help with insurance benefits verification, prior authorization requirements, the appeals process and insurance changes
- Co-pay help for eligible people with commercial insurance, through GPS. The terms posted on Pfizer's page list an expiry date of December 31, 2024, and GPS can explain what is offered now
- Under the posted terms, co-pay help is not open to people on Medicare, Medicaid, TRICARE, Veterans Affairs health care or other state or federal insurance, or to cash-paying patients
- The Pfizer Patient Assistance Program, Elelyso at no cost for qualified uninsured or government-insured people who meet financial rules and live in the US
- A list of infusion sites in your area, and coordination so that Elelyso and supplies are at the site
- A check of home-health benefits with your insurer, and contact with a specialty pharmacy to set up at-home infusions if the insurer approves
- Help researching transportation to and from infusions. GPS does not give the infusions itself
- A Pfizer co-pay FAQ dated March 2024 lists GPS phone hours as Monday to Friday, 8 AM to 6 PM Eastern. It also says co-pay enrollment renews automatically each year if you still qualify PfizerCopay.com FAQs
Questions prescribers' offices ask about Elelyso
What is the Elelyso dose for type 1 Gaucher disease?
The December 2025 label gives 60 units/kg (actual body weight) IV every other week as a 60- to 120-minute infusion for treatment-naive patients 4 years and older. Patients switching from a stable imiglucerase dosage start at the same units/kg dosage, then continue every other week. Dosage adjustments can be based on each patient's therapeutic goals.
What infusion rate and volume does the Elelyso label specify?
The December 2025 label sets a minimum of 60 minutes through an in-line low protein-binding 0.2 micron filter. Adults start at 1.2mL/minute and may increase to a maximum of 2.2mL/minute once tolerability is established. Pediatric patients under 30kg stay at 1mL/minute; at 30kg or more they start at 1mL/minute, maximum 2mL/minute. Final volume is 100 to 120mL for pediatric patients and 130 to 150mL for adults, not above 200mL.
Is premedication required before Elelyso infusions?
No fixed requirement: section 2.1 of the December 2025 label says to consider pretreatment with antihistamines and/or corticosteroids to reduce the risk of hypersensitivity reactions. Trial patients were not routinely pretreated, and 21 of 72 (29%) had hypersensitivity reactions, including 2 (3%) with signs consistent with anaphylaxis. For severe reactions, discontinue and treat immediately, including epinephrine.
Can Elelyso be infused at home?
The December 2025 label requires initiation in a healthcare setting with medical monitoring and access to CPR equipment, and sets no number of infusions before a change of site. Administration should be supervised by a provider knowledgeable in managing anaphylaxis. Pfizer GPS can verify home-health benefits and, if the insurer approves, contact a specialty pharmacy to set up at-home infusions.
What are the Elelyso prior authorization criteria?
The FEP Blue policy shown here, 5.85.014 effective April 1, 2026, approves 2 years for patients 4 years and older with type 1 Gaucher disease. It requires no dual therapy with another type 1 Gaucher medication (Cerdelga, Cerezyme, VPRIV, Zavesca or Yargesa). Renewal uses the same requirements, and all other indications are considered investigational.
Free email alert
Get an email when the Elelyso label changes
One email the day the FDA revises the Elelyso prescribing information, with a summary of what changed. No trial alerts or newsletter, and you can stop anytime.
Label changes for Elelyso only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Sources
- DailyMed - ELELYSO- taliglucerase alfa injection, powder, lyophilized, for solution (updated December 29, 2025, SPL version 31, prescribing information revised 12/2025), Pfizer Laboratories Div Pfizer Inc, via DailyMed, 2025-12-29.
- ELELYSO (taliglucerase alfa) for injection, for intravenous use, prescribing information, revised 7/2024, FDA, Drugs@FDA, 2024-07-10.
- Pfizer GPS | ELELYSO® (taliglucerase alfa) for injection | Risk Info, Pfizer, 2025.
- Resources | ELELYSO® (taliglucerase alfa) for injection | Safety Info (Access and Support for ELELYSO Patients), Pfizer, 2026.
- Patient Support Offerings | Pfizer for Professionals, Pfizer, 2026.
- PfizerCopay.com Frequently Asked Questions (FAQs) (PP-BEQ-USA-0061, March 2024), Pfizer, 2024-03.
- Elelyso, FEP pharmacy policy 5.85.014, Blue Cross Blue Shield Association, Federal Employee Program, 2026-04-01.
- BLA 022458/S-034 supplement approval letter, updates to subsections 8.1 Pregnancy and 8.2 Lactation, FDA, 2025-12-22.
- BLA 022458/S-033 supplement approval letter, change to the observation time for anaphylactic reactions in subsection 5.1, FDA, 2025-01-17.
- BLA 022458/S-031 supplement approval letter, enzyme replacement therapy class safety labeling change for hypersensitivity, FDA, 2024-07-10.
A reference drawn from the December 29, 2025 label, the drugmaker's published program and one public insurer policy shown as an example, checked on November 11, 2026. Labels and policies change; the label on DailyMed and the plan's current policy govern. Trial Friend is not a medical provider. It reports what these documents say and does not judge whether a drug is safe or right for any patient; that is the prescriber's decision. Not a substitute for the prescribing information.